Corvus Pharmaceuticals (CRVS) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 12.8% versus a loss of 29.0%. Over five years, CRVS leads with a +183.6% price change compared with +39.0% for PHAR. Pharming Group N.V. is the larger company by market cap ($816.8 million vs $815.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | PHAR |
|---|---|---|
| Share price | $9.67 | $11.54 |
| Market cap | $815.69M | $816.78M |
| 1-day change | -3.40% | -5.10% |
| YTD return | +25.58% | -34.69% |
| 1-year return | +12.84% | -29.03% |
| 5-year return | +183.58% | +39.04% |
| P/E ratio (TTM) | — | 36.06 |
| Forward P/E | — | 64.11 |
| EPS (TTM) | $-0.72 | $0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.13M |
| Revenue growth (YoY) | — | +26.56% |
| Net income (latest FY) | $-15.28M | $2.85M |
| Gross margin | — | 87.90% |
| Operating margin | — | 6.87% |
| Net margin | — | 0.76% |
| 52-week high | $26.95 | $21.34 |
| 52-week low | $6.39 | $9.11 |
| Distance from 52-week high | -64.12% | -45.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +225.75% | +209.36% |
| Average volume | 1.05M | 21.33K |
| Shares outstanding | 84.35M | 70.78M |
| Employees | 37 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed PHAR by 41.9 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
CRVS vs PHAR FAQ
Which is bigger, Corvus Pharmaceuticals or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $816.78M compared with $815.69M for Corvus Pharmaceuticals (CRVS).
Which stock has performed better over the past year, CRVS or PHAR?
CRVS returned +12.84% over the past 12 months, compared with -29.03% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.